Chengdu Kanghua Biological Products Co Ltd - ESG Rating & Company Profile powered by AI
The Disclosure rating covers 17 United Nations Sustainable Development Goals including: 'Quality Education', 'Reduced Inequalities' and 'Life below Water'. Detailed ESG analysis of Chengdu Kanghua Biological Products Co Ltd are reached by signing up for free. The webpage of Chengdu Kanghua Biological Products Co Ltd was assembled by All Street Sevva using cutting edge artificial intelligence.
Chengdu Kanghua Biological Products Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | Chengdu Kanghua Biological Products Co Ltd | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Chengdu Kanghua Biological Products Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Chengdu Kanghua Biological Products Co Ltd disclose current and historical energy intensity?
Does Chengdu Kanghua Biological Products Co Ltd report the average age of the workforce?
Does Chengdu Kanghua Biological Products Co Ltd reference operational or capital allocation in relation to climate change?
Does Chengdu Kanghua Biological Products Co Ltd disclose its ethnicity pay gap?
Does Chengdu Kanghua Biological Products Co Ltd disclose cybersecurity risks?
Does Chengdu Kanghua Biological Products Co Ltd offer flexible work?
Does Chengdu Kanghua Biological Products Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Chengdu Kanghua Biological Products Co Ltd disclose the number of employees in R&D functions?
Does Chengdu Kanghua Biological Products Co Ltd conduct supply chain audits?
Does Chengdu Kanghua Biological Products Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Chengdu Kanghua Biological Products Co Ltd conduct 360 degree staff reviews?
Does Chengdu Kanghua Biological Products Co Ltd disclose the individual responsible for D&I?
Does Chengdu Kanghua Biological Products Co Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Chengdu Kanghua Biological Products Co Ltd disclose current and / or historical scope 2 emissions?
Does Chengdu Kanghua Biological Products Co Ltd disclose water use targets?
Does Chengdu Kanghua Biological Products Co Ltd have careers partnerships with academic institutions?
Did Chengdu Kanghua Biological Products Co Ltd have a product recall in the last two years?
Does Chengdu Kanghua Biological Products Co Ltd disclose incidents of discrimination?
Does Chengdu Kanghua Biological Products Co Ltd allow for Work Councils/Collective Agreements to be formed?
Has Chengdu Kanghua Biological Products Co Ltd issued a profit warning in the past 24 months?
Does Chengdu Kanghua Biological Products Co Ltd disclose parental leave metrics?
Does Chengdu Kanghua Biological Products Co Ltd disclose climate scenario or pathway analysis?
Does Chengdu Kanghua Biological Products Co Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Chengdu Kanghua Biological Products Co Ltd disclose the pay ratio of women to men?
Does Chengdu Kanghua Biological Products Co Ltd support suppliers with sustainability related research and development?
Does Chengdu Kanghua Biological Products Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Chengdu Kanghua Biological Products Co Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Chengdu Kanghua Biological Products Co Ltd involved in embryonic stem cell research?
Does Chengdu Kanghua Biological Products Co Ltd disclose GHG and Air Emissions intensity?
Does Chengdu Kanghua Biological Products Co Ltd disclose its waste policy?
Does Chengdu Kanghua Biological Products Co Ltd report according to TCFD requirements?
Does Chengdu Kanghua Biological Products Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Chengdu Kanghua Biological Products Co Ltd disclose energy use targets?
Does Chengdu Kanghua Biological Products Co Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Chengdu Kanghua Biological Products Co Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Chengdu Kanghua Biological Products Co Ltd
These potential risks are based on the size, segment and geographies of the company.
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines without preservatives, which completed phase III clinical trials; and human H5N1 influenza vaccine that completed pre-clinical studies. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.